Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1

Total Page:16

File Type:pdf, Size:1020Kb

Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1 RESEARCH ARTICLE Single-Cell Analysis of the Multicellular Ecosystem in Viral Carcinogenesis by HTLV-1 Junji Koya1, Yuki Saito1,2, Takuro Kameda3, Yasunori Kogure1, Mitsuhiro Yuasa1,4, Joji Nagasaki5, Marni B. McClure1, Sumito Shingaki1, Mariko Tabata1,6, Yuki Tahira3, Keiichi Akizuki3, Ayako Kamiunten3, Masaaki Sekine3, Kotaro Shide3, Yoko Kubuki3, Tomonori Hidaka3, Akira Kitanaka7, Nobuaki Nakano8, Atae Utsunomiya8, Yosuke Togashi5, Seishi Ogawa9, Kazuya Shimoda3, and Keisuke Kataoka1,10 Downloaded from https://bloodcancerdiscov.aacrjournals.org by guest on October 1, 2021. Copyright 2021 American Copyright 2021 by AssociationAmerican for Association Cancer Research. for Cancer Research. ABSTRACT Premalignant clonal expansion of human T-cell leukemia virus type-1 (HTLV-1)– infected cells occurs before viral carcinogenesis. Here we characterize premalig- nant cells and the multicellular ecosystem in HTLV-1 infection with and without adult T-cell leukemia/ lymphoma (ATL) by genome sequencing and single-cell simultaneous transcriptome and T/B-cell recep- tor sequencing with surface protein analysis. We distinguish malignant phenotypes caused by HTLV-1 infection and leukemogenesis and dissect clonal evolution of malignant cells with different clinical behavior. Within HTLV-1–infected cells, a regulatory T-cell phenotype associates with premalignant clonal expansion. We also delineate differences between virus- and tumor-related changes in the nonmalig- nant hematopoietic pool, including tumor-specific myeloid propagation. In a newly generated conditional knockout mouse model recapitulating T-cell–restricted CD274 (encoding PD-L1) gene lesions found in ATL, we demonstrate that PD-L1 overexpressed by T cells is transferred to surrounding cells, leading to their PD-L1 upregulation. Our findings provide insights into clonal evolution and immune landscape of multistep virus carcinogenesis. SIGNIFICANCE: Our multimodal single-cell analyses comprehensively dissect the cellular and molecular alterations of the peripheral blood in HTLV-1 infection, with and without progression to leukemia. This study not only sheds light on premalignant clonal expansion in viral carcinogenesis, but also helps to devise novel diagnostic and therapeutic strategies for HTLV-1–related disorders. INTRODUCTION Besides viral carcinogenesis, recent studies described somatic mutations in normal tissues, such as the hematopoietic and Oncogenic viral infections, such as human T-cell leukemia gastrointestinal systems, pointing to a critical role of prema- virus type-1 (HTLV-1), are responsible for 10% to 15% of human lignant clonal expansion in diverse oncogenic processes (5, cancers worldwide (1). These viruses can induce carcinogenesis 6). However, the biological properties and molecular basis by various mechanisms, such as chronic inflammation, cellu- of premalignant clonal expansion are not well characterized. lar transformation, and immune suppression (2). Accumulat- HTLV-1 is a retrovirus infecting approximately 5 to 20 million ing evidence suggests that clonal expansion of infected cells people worldwide, particularly in endemic regions (7). This precedes malignancy and contributes to tumorigenesis (3, 4). virus preferentially targets CD4+ T cells and is associated with a variety of diseases, ranging from inflammatory disorders to adult T-cell leukemia/lymphoma (ATL). ATL is an aggressive 1Division of Molecular Oncology, National Cancer Center Research Insti- T-cell neoplasm evolving after a long latency of >30 to 50 tute, Tokyo, Japan. 2Department of Gastroenterology, Keio University years. Even before ATL onset, premalignant HTLV-1–infected School of Medicine, Tokyo, Japan. 3Division of Hematology, Diabetes, and clones bearing driver mutations can be detected (4), offering Endocrinology, Department of Internal Medicine, Faculty of Medicine, Uni- a unique opportunity to functionally dissect premalignant 4 versity of Miyazaki, Miyazaki, Japan. Department of Pathology, Graduate clonal expansion in multistep viral carcinogenesis. However, School of Medicine, The University of Tokyo, Tokyo, Japan. 5Chiba Cancer Center, Research Institute, Chiba, Japan. 6Department of Urology, Graduate as only a small proportion (usually <1%–5%) of peripheral School of Medicine, The University of Tokyo, Tokyo, Japan. 7Department of blood mononuclear cells (PBMC) of asymptomatic carriers Laboratory Medicine, Kawasaki Medical School, Kurashiki, Japan. 8Depart- (AC) contain integrated proviral DNA (8), the phenotypical ment of Hematology, Imamura General Hospital, Kagoshima, Japan. and functional evaluation of HTLV-1–infected cells is difficult. 9Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan. 10Division of Hematology, Department of Efficient cytotoxic T-lymphocyte (CTL) response to HTLV-1 Medicine, Keio University School of Medicine, Tokyo, Japan. has been reported to limit the proviral load and the risk of Note: Supplementary data for this article are available at Blood Cancer associated diseases (9). By contrast, ATL patients are severely Discovery Online (https://bloodcancerdiscov.aacrjournals.org/). immunocompromised, frequently contracting opportunistic J. Koya and Y. Saito contributed equally to this article. infections (10). These observations emphasize the relevance K. Kataoka is the senior author of this article. of immune dynamics in HTLV-1–related diseases. This view Corresponding Author: Keisuke Kataoka, Division of Molecular Oncology, is supported by genetic studies showing frequent alterations National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo in immune molecules, such as structural variations (SV) trun- 104-0045, Japan. Phone: 81-3-3542-2511; Fax: 81-3-5565-0727; E-mail: cating the CD274 3′-untranslated regions (UTR) in ATL (11, [email protected] 12). However, although many efforts have been devoted to Blood Cancer Discov 2021;2:1–18 CTL characterization, the entire composition and functional doi: 10.1158/2643-3230.BCD-21-0044 heterogeneity of the immune microenvironment in HTLV-1 This open access article is distributed under the Creative Commons Attribution- infection and ATL remain elusive. NonCommercial-NoDerivatives License 4.0 International (CC BY-NC-ND). Recent advances in single-cell analysis provide an avenue to ©2021 The Authors; Published by the American Association for Cancer Research elucidate phenotypic features at a cellular resolution, allowing SEPTEMBER 2021 BLOOD CANCER DISCOVERY | OF2 Downloaded from https://bloodcancerdiscov.aacrjournals.org by guest on October 1, 2021. Copyright 2021 American Association for Cancer Research. RESEARCH ARTICLE Koya et al. profound understanding of tumor heterogeneity and microen- ples were grouped into the same clusters (Fig. 1B and C). vironment in cancer (13). Particularly, cellular indexing of tran- By contrast, nonmalignant cells, including those from ACs scriptomes and epitopes by sequencing (CITE-seq) is a recently and HDs, were classified into the same clusters according to developed tool for exploring transcriptomic and surface prot- their lineage, suggesting their transcriptomic similarity among eomic states in the same single cell (14). Also, single-cell T/B- patients. Almost all malignant clusters expressed HTLV-1 HBZ cell receptor (TCR/BCR) sequencing (scTCR/BCR-seq) enables (Fig. 1C). Although almost no cells were classified into malig- detection of T/B-cell clonal expansion patterns through identi- nant clusters in ACs or HDs, malignant cells accounted for cal TCR/BCR sequence detection (15), which can be utilized to 15% to 99% (median 82%) of the total cells in ATL, which were track clonal evolution in lymphoid malignancy. lower in smoldering than in other subtypes (Supplementary Here, to investigate the cellular and molecular architecture in Fig. S1D and S1E). Single-cell mutation and CNA estimation HTLV-1 infection and ATL, we performed multimodal single-cell revealed somatic alterations almost exclusively in malignant analysis, evaluating transcriptome and many surface markers. clusters, consistent with the bulk sequencing and SNP array Combined with scTCR-seq, our approach deciphers functional results (Supplementary Fig. S1F and S1G), confirming success- heterogeneity of HTLV-1–infected premalignant cells and the ful separation of malignant from nonmalignant cells. hierarchy and clonal evolution of malignant cells. Simultaneous mRNA and protein assessment delineates discordant regula- Lineage-Specific Regulation of mRNA and tion of their expression levels, particularly in myeloid lineage. In ADT Levels addition, we reveal variegated alterations in the immune micro- Protein abundance is a more direct determinant of cellular environment, including a novel mode of PD-L1 upregulation in functions but cannot necessarily be inferred from mRNA surrounding cells by CD274 SV-harboring tumors. level due to posttranscriptional processes (16). CITE-seq anal- ysis in healthy, virally infected, and leukemic states enables a RESULTS detailed comparison of mRNA and ADT level changes in vari- ous cell types. At the single-cell level, ADT was less prone to Landscape of the Multicellular Ecosystem in dropout than mRNA, conferring higher sensitivity for many HTLV-1 Infection and ATL surface markers (Supplementary Fig. S2A; Supplementary To delineate the multicellular ecosystem of HTLV-1 carrier Table S2). As expected, more than two thirds of genes showed state and ATL, we constructed transcriptomic, surface phe- strong positive
Recommended publications
  • Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
    Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only.
    [Show full text]
  • HCST (NM 001007469) Human Recombinant Protein Product Data
    OriGene Technologies, Inc. 9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 [email protected] EU: [email protected] CN: [email protected] Product datasheet for TP319253 HCST (NM_001007469) Human Recombinant Protein Product data: Product Type: Recombinant Proteins Description: Recombinant protein of human hematopoietic cell signal transducer (HCST), transcript variant 2 Species: Human Expression Host: HEK293T Tag: C-Myc/DDK Predicted MW: 7.3 kDa Concentration: >50 ug/mL as determined by microplate BCA method Purity: > 80% as determined by SDS-PAGE and Coomassie blue staining Buffer: 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol Preparation: Recombinant protein was captured through anti-DDK affinity column followed by conventional chromatography steps. Storage: Store at -80°C. Stability: Stable for 12 months from the date of receipt of the product under proper storage and handling conditions. Avoid repeated freeze-thaw cycles. RefSeq: NP_001007470 Locus ID: 10870 UniProt ID: Q9UBK5 RefSeq Size: 521 Cytogenetics: 19q13.12 RefSeq ORF: 279 Synonyms: DAP10; KAP10; PIK3AP This product is to be used for laboratory only. Not for diagnostic or therapeutic use. View online » ©2021 OriGene Technologies, Inc., 9620 Medical Center Drive, Ste 200, Rockville, MD 20850, US 1 / 2 HCST (NM_001007469) Human Recombinant Protein – TP319253 Summary: This gene encodes a transmembrane signaling adaptor that contains a YxxM motif in its cytoplasmic domain. The encoded protein may form part of the immune recognition receptor complex with the C-type lectin-like receptor NKG2D. As part of this receptor complex, this protein may activate phosphatidylinositol 3-kinase dependent signaling pathways through its intracytoplasmic YxxM motif.
    [Show full text]
  • Characterization of FLT3-Itdmut Acute Myeloid Leukemia
    Travaglini et al. Blood Cancer Journal (2020) 10:85 https://doi.org/10.1038/s41408-020-00352-9 Blood Cancer Journal ARTICLE Open Access Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells Serena Travaglini1, Daniela Francesca Angelini 2, Valentina Alfonso1, Gisella Guerrera2,SerenaLavorgna1, Mariadomenica Divona1, Anna Maria Nardozza1, Maria Irno Consalvo1, Emiliano Fabiani1,MarcoDeBardi 2, Benedetta Neri3,FabioForghieri4, Francesco Marchesi5, Giovangiacinto Paterno1, Raffaella Cerretti1, Eva Barragan 6, Valentina Fiori7,SabrinaDominici7, Maria Ilaria Del Principe1, Adriano Venditti 1, Luca Battistini2, William Arcese1, Francesco Lo-Coco1, Maria Teresa Voso 1,2 and Tiziana Ottone1,2 Abstract Acute myeloid leukemia (AML) with FLT3-ITD mutations (FLT3-ITDmut) remains a therapeutic challenge, with a still high relapse rate, despite targeted treatment with tyrosine kinase inhibitors. In this disease, the CD34/CD123/CD25/CD99+ leukemic precursor cells (LPCs) phenotype predicts for FLT3-ITD-positivity. The aim of this study was to characterize the distribution of FLT3-ITD mutation in different progenitor cell subsets to shed light on the subclonal architecture of FLT3-ITDmut AML. Using high-speed cell sorting, we sequentially purified LPCs and CD34+ progenitors in samples from patients with FLT3-ITDmut AML (n = 12). A higher FLT3-ITDmut load was observed within CD34/CD123/CD25/CD99+ LPCs, as compared to CD34+ progenitors (CD123+/−,CD25−,CD99low/−)(p = 0.0005) and mononuclear cells (MNCs) (p < 0.0001). This was associated with significantly increased CD99 mean fluorescence intensity in LPCs. 1234567890():,; 1234567890():,; 1234567890():,; 1234567890():,; Significantly higher FLT3-ITDmut burden was also observed in LPCs of AML patients with a small FLT3-ITDmut clones at diagnosis.
    [Show full text]
  • Single-Cell RNA Sequencing Demonstrates the Molecular and Cellular Reprogramming of Metastatic Lung Adenocarcinoma
    ARTICLE https://doi.org/10.1038/s41467-020-16164-1 OPEN Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma Nayoung Kim 1,2,3,13, Hong Kwan Kim4,13, Kyungjong Lee 5,13, Yourae Hong 1,6, Jong Ho Cho4, Jung Won Choi7, Jung-Il Lee7, Yeon-Lim Suh8,BoMiKu9, Hye Hyeon Eum 1,2,3, Soyean Choi 1, Yoon-La Choi6,10,11, Je-Gun Joung1, Woong-Yang Park 1,2,6, Hyun Ae Jung12, Jong-Mu Sun12, Se-Hoon Lee12, ✉ ✉ Jin Seok Ahn12, Keunchil Park12, Myung-Ju Ahn 12 & Hae-Ock Lee 1,2,3,6 1234567890():,; Advanced metastatic cancer poses utmost clinical challenges and may present molecular and cellular features distinct from an early-stage cancer. Herein, we present single-cell tran- scriptome profiling of metastatic lung adenocarcinoma, the most prevalent histological lung cancer type diagnosed at stage IV in over 40% of all cases. From 208,506 cells populating the normal tissues or early to metastatic stage cancer in 44 patients, we identify a cancer cell subtype deviating from the normal differentiation trajectory and dominating the metastatic stage. In all stages, the stromal and immune cell dynamics reveal ontological and functional changes that create a pro-tumoral and immunosuppressive microenvironment. Normal resident myeloid cell populations are gradually replaced with monocyte-derived macrophages and dendritic cells, along with T-cell exhaustion. This extensive single-cell analysis enhances our understanding of molecular and cellular dynamics in metastatic lung cancer and reveals potential diagnostic and therapeutic targets in cancer-microenvironment interactions. 1 Samsung Genome Institute, Samsung Medical Center, Seoul 06351, Korea.
    [Show full text]
  • CD29 Identifies IFN-Γ–Producing Human CD8+ T Cells With
    + CD29 identifies IFN-γ–producing human CD8 T cells with an increased cytotoxic potential Benoît P. Nicoleta,b, Aurélie Guislaina,b, Floris P. J. van Alphenc, Raquel Gomez-Eerlandd, Ton N. M. Schumacherd, Maartje van den Biggelaarc,e, and Monika C. Wolkersa,b,1 aDepartment of Hematopoiesis, Sanquin Research, 1066 CX Amsterdam, The Netherlands; bLandsteiner Laboratory, Oncode Institute, Amsterdam University Medical Center, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands; cDepartment of Research Facilities, Sanquin Research, 1066 CX Amsterdam, The Netherlands; dDivision of Molecular Oncology and Immunology, Oncode Institute, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands; and eDepartment of Molecular and Cellular Haemostasis, Sanquin Research, 1066 CX Amsterdam, The Netherlands Edited by Anjana Rao, La Jolla Institute for Allergy and Immunology, La Jolla, CA, and approved February 12, 2020 (received for review August 12, 2019) Cytotoxic CD8+ T cells can effectively kill target cells by producing therefore developed a protocol that allowed for efficient iso- cytokines, chemokines, and granzymes. Expression of these effector lation of RNA and protein from fluorescence-activated cell molecules is however highly divergent, and tools that identify and sorting (FACS)-sorted fixed T cells after intracellular cytokine + preselect CD8 T cells with a cytotoxic expression profile are lacking. staining. With this top-down approach, we performed an un- + Human CD8 T cells can be divided into IFN-γ– and IL-2–producing biased RNA-sequencing (RNA-seq) and mass spectrometry cells. Unbiased transcriptomics and proteomics analysis on cytokine- γ– – + + (MS) analyses on IFN- and IL-2 producing primary human producing fixed CD8 T cells revealed that IL-2 cells produce helper + + + CD8 Tcells.
    [Show full text]
  • Genetic Correlations Reveal the Shared Genetic Architecture of Transcription in Human Peripheral Blood
    Hemani, G. (2017). Genetic correlations reveal the shared genetic architecture of transcription in human peripheral blood. Nature Communications, 8, [483]. https://doi.org/10.1038/s41467-017-00473- z Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1038/s41467-017-00473-z Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via Nature Publishing Group at https://www.nature.com/articles/s41467-017-00473-z . Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ ARTICLE DOI: 10.1038/s41467-017-00473-z OPEN Genetic correlations reveal the shared genetic architecture of transcription in human peripheral blood Samuel W. Lukowski 1, Luke R. Lloyd-Jones1,2, Alexander Holloway2, Holger Kirsten3,4, Gibran Hemani 5,6, Jian Yang 1,2, Kerrin Small 7, Jing Zhao8, Andres Metspalu9, Emmanouil T. Dermitzakis10, Greg Gibson 8, Timothy D. Spector7, Joachim Thiery4,11, Markus Scholz 3,4, Grant W. Montgomery1,12, Tonu Esko 9, Peter M. Visscher 1,2 & Joseph E. Powell1,2 Transcript co-expression is regulated by a combination of shared genetic and environmental factors. Here, we estimate the proportion of co-expression that is due to shared genetic variance.
    [Show full text]
  • Blood Flow Guides Sequential Support of Neutrophil Arrest and Diapedesis
    RESEARCH ARTICLE Blood flow guides sequential support of neutrophil arrest and diapedesis by PILR-b 1 and PILR-a Yu-Tung Li, Debashree Goswami†, Melissa Follmer, Annette Artz, Mariana Pacheco-Blanco, Dietmar Vestweber* Vascular Cell Biology, Max Planck Institute of Molecular Biomedicine, Mu¨ nster, Germany Abstract Arrest of rapidly flowing neutrophils in venules relies on capturing through selectins and chemokine-induced integrin activation. Despite a long-established concept, we show here that gene inactivation of activating paired immunoglobulin-like receptor (PILR)-b1 nearly halved the efficiency of neutrophil arrest in venules of the mouse cremaster muscle. We found that this receptor binds to CD99, an interaction which relies on flow-induced shear forces and boosts chemokine-induced b2-integrin-activation, leading to neutrophil attachment to endothelium. Upon arrest, binding of PILR-b1 to CD99 ceases, shifting the signaling balance towards inhibitory PILR-a. This enables integrin deactivation and supports cell migration. Thus, flow-driven shear forces guide sequential signaling of first activating PILR-b1 followed by inhibitory PILR-a to prompt neutrophil arrest and then transmigration. This doubles the efficiency of selectin-chemokine driven neutrophil arrest by PILR-b1 and then supports transition to migration by PILR-a. DOI: https://doi.org/10.7554/eLife.47642.001 *For correspondence: [email protected] Present address: †Center for Global Infectious Disease Introduction Research, Seattle Childrens Host defense against pathogens depends on the recruitment of leukocytes to sites of infections Research Institute, Seattle, (Ley et al., 2007). Selectins capture leukocytes to the endothelial cell surface by binding to glyco- United States conjugates (McEver, 2015).
    [Show full text]
  • IHC Test Menu
    Immunohistochemistry Test Menu A Alpha fetoprotein [I AFP] CD99 Ewings sarcoma PNET [I CD99] Anaplastic lymphoma kinase -1 [I ALK] CD103 Integrin alpha E [I CD103] Androgen receptor [I ANDRO]* CD117 C-Kit, myeloid, mast cells, GIST [I CD117] Annexin A1, hairy cell, B cell lymphoma [I ANXA1] CD138 plasma cells, subset epithelial cells [I CD138] Anti-Arginase-1 [I ARGINASE] CD163 histiocytes [I CD163] CDK4 cyclin-depdendent kinase-4, clone DCS-31 [I CDK4] B CDX2 colorectal carcinoma [I CDX2] BCL2 follicular lymphoma, apoptosis inhibiting protein [I BCL2] Chromogranin A [I CHROGRAN] BCL6 follicle center B-cell [I BCL6] CMYC C-MYC oncoprotein [I CMYC] BER EP4 Epithelial antigen [I BER EP4] Collagen IV, basement membrane protein [I CLLGIV] BRAF [I V600E] Cyclin D1/PRAD1 mantle cell lymphoma [I CYCLIN] Cytokeratin 5/6, squamous, mesothelial [I CK5/6] C Cytokeratin 7, 54kD [I CK7] CA 19-9 pancreas, liver, ovary, lung tumors [I CA19 9] Cytokeratin 7/8 CAM5.2 [I CAM 5.2] CA 125 epitheliod malignancies ovary, breast [I CA125] Cytokeratin 8, 35BH11 [I CK8] Calcitonin [I CALCT] Cytokeratin 8/18, adenocarcinoma [I CK8/18] Caldesmon, smooth muscle [I CALDSM] Cytokeratin 19 [I CK19] Calretinin; Calcium binding protein [I CALRT] Cytokeratin 20 [I CK20] CAM 5.2 Cytokeratin 7/Cytokeratin 8 [I CAM 5.2] Cytokeratin cocktail, PAN (AE1/AE3) [I AE1/AE3] Carcinoembryonic antigen (CEA) [I CEA] Cytokeratin high molecular weight; 34BE12 [I CK HMW] Cathepsin D, breast carcinoma [I CATHD] Cytomegalovirus [I CMV] CD1a cortical thymocyctes, Langerhans cells [I CD1a]
    [Show full text]
  • WO 2018/067991 Al 12 April 2018 (12.04.2018) W !P O PCT
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2018/067991 Al 12 April 2018 (12.04.2018) W !P O PCT (51) International Patent Classification: achusetts 021 15 (US). THE BROAD INSTITUTE, A61K 51/10 (2006.01) G01N 33/574 (2006.01) INC. [US/US]; 415 Main Street, Cambridge, Massachu C07K 14/705 (2006.01) A61K 47/68 (2017.01) setts 02142 (US). MASSACHUSETTS INSTITUTE OF G01N 33/53 (2006.01) TECHNOLOGY [US/US]; 77 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). (21) International Application Number: PCT/US2017/055625 (72) Inventors; and (71) Applicants: KUCHROO, Vijay K. [IN/US]; 30 Fairhaven (22) International Filing Date: Road, Newton, Massachusetts 02149 (US). ANDERSON, 06 October 2017 (06.10.2017) Ana Carrizosa [US/US]; 110 Cypress Street, Brookline, (25) Filing Language: English Massachusetts 02445 (US). MADI, Asaf [US/US]; c/o The Brigham and Women's Hospital, Inc., 75 Francis (26) Publication Language: English Street, Boston, Massachusetts 021 15 (US). CHIHARA, (30) Priority Data: Norio [US/US]; c/o The Brigham and Women's Hospital, 62/405,835 07 October 2016 (07.10.2016) US Inc., 75 Francis Street, Boston, Massachusetts 021 15 (US). REGEV, Aviv [US/US]; 15a Ellsworth Ave, Cambridge, (71) Applicants: THE BRIGHAM AND WOMEN'S HOSPI¬ Massachusetts 02139 (US). SINGER, Meromit [US/US]; TAL, INC. [US/US]; 75 Francis Street, Boston, Mass c/o The Broad Institute, Inc., 415 Main Street, Cambridge, (54) Title: MODULATION OF NOVEL IMMUNE CHECKPOINT TARGETS CD4 FIG.
    [Show full text]
  • Immunohistochemistry Stain Offerings
    immunohistochemistry stain offerings TRUSTED PATHOLOGISTS. INVALUABLE ANSWERS.™ MARCHMAY 20172021 www.aruplab.com/ap-ihcaruplab.com/ap-ihc InformationInformation in this brochurein this brochure is current is current as of as May of March 2021. 2017. All content All content is subject is subject to tochange. change. Please contactPlease ARUPcontact ClientARUP Services Client Services at 800-522-2787 at (800) 522-2787 with any with questions any questions or concerns.or concerns. ARUP LABORATORIES As a nonprofit, academic institution of the University of Utah and its Department We believe in of Pathology, ARUP believes in collaborating, sharing and contributing to laboratory science in ways that benefit our clients and their patients. collaborating, Our test menu is one of the broadest in the industry, encompassing more sharing and than 3,000 tests, including highly specialized and esoteric assays. We offer comprehensive testing in the areas of genetics, molecular oncology, pediatrics, contributing pain management, and more. to laboratory ARUP’s clients include many of the nation’s university teaching hospitals and children’s hospitals, as well as multihospital groups, major commercial science in ways laboratories, and group purchasing organizations. We believe that healthcare should be delivered as close to the patient as possible, which is why we support that provide our clients’ efforts to be the principal healthcare provider in the communities they serve by offering highly complex assays and accompanying consultative support. the best value Offering analytics, consulting, and decision support services, ARUP provides for the patient. clients with the utilization management tools necessary to prosper in this time of value-based care.
    [Show full text]
  • Plasma Cells in Vitro Generation of Long-Lived Human
    Downloaded from http://www.jimmunol.org/ by guest on September 24, 2021 is online at: average * The Journal of Immunology , 32 of which you can access for free at: 2012; 189:5773-5785; Prepublished online 16 from submission to initial decision 4 weeks from acceptance to publication November 2012; doi: 10.4049/jimmunol.1103720 http://www.jimmunol.org/content/189/12/5773 In Vitro Generation of Long-lived Human Plasma Cells Mario Cocco, Sophie Stephenson, Matthew A. Care, Darren Newton, Nicholas A. Barnes, Adam Davison, Andy Rawstron, David R. Westhead, Gina M. Doody and Reuben M. Tooze J Immunol cites 65 articles Submit online. Every submission reviewed by practicing scientists ? is published twice each month by Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts http://jimmunol.org/subscription http://www.jimmunol.org/content/suppl/2012/11/16/jimmunol.110372 0.DC1 This article http://www.jimmunol.org/content/189/12/5773.full#ref-list-1 Information about subscribing to The JI No Triage! Fast Publication! Rapid Reviews! 30 days* Why • • • Material References Permissions Email Alerts Subscription Supplementary The Journal of Immunology The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2012 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. This information is current as of September 24, 2021. The Journal of Immunology In Vitro Generation of Long-lived Human Plasma Cells Mario Cocco,*,1 Sophie Stephenson,*,1 Matthew A.
    [Show full text]
  • Diagnostic Accuracy of a Panel of Immunohistochemical and Molecular Markers to Distinguish Merkel Cell Carcinoma from Other Neuroendocrine Carcinomas
    Modern Pathology (2019) 32:499–510 https://doi.org/10.1038/s41379-018-0155-y ARTICLE Diagnostic accuracy of a panel of immunohistochemical and molecular markers to distinguish Merkel cell carcinoma from other neuroendocrine carcinomas 1,2,3 4 1 3 3 Thibault Kervarrec ● Anne Tallet ● Elodie Miquelestorena-Standley ● Roland Houben ● David Schrama ● 5 2 6 7 8 Thilo Gambichler ● Patricia Berthon ● Yannick Le Corre ● Ewa Hainaut-Wierzbicka ● Francois Aubin ● 9 10 11 12 12 Guido Bens ● Flore Tabareau-Delalande ● Nathalie Beneton ● Gaëlle Fromont ● Flavie Arbion ● 13 2 2,14 1,2 Emmanuelle Leteurtre ● Antoine Touzé ● Mahtab Samimi ● Serge Guyétant Received: 14 July 2018 / Revised: 2 September 2018 / Accepted: 3 September 2018 / Published online: 22 October 2018 © United States & Canadian Academy of Pathology 2018 Abstract Merkel cell carcinoma is a rare neuroendocrine carcinoma of the skin mostly induced by Merkel cell polyomavirus integration. Cytokeratin 20 (CK20) positivity is currently used to distinguish Merkel cell carcinomas from other neuroendocrine carcinomas. However, this distinction may be challenging in CK20-negative cases and in cases without a 1234567890();,: 1234567890();,: primary skin tumor. The objectives of this study were first to evaluate the diagnostic accuracy of previously described markers for the diagnosis of Merkel cell carcinoma and second to validate these markers in the setting of difficult-to- diagnose Merkel cell carcinoma variants. In a preliminary set (n = 30), we assessed optimal immunohistochemical patterns (CK20, thyroid transcription factor 1 [TTF-1], atonal homolog 1 [ATOH1], neurofilament [NF], special AT-rich sequence- binding protein 2 [SATB2], paired box protein 5, terminal desoxynucleotidyl transferase, CD99, mucin 1, and Merkel cell polyomavirus-large T antigen) and Merkel cell polyomavirus load thresholds (real-time PCR).
    [Show full text]